We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
10 October 2018
On 27 March 2017 the Federal Court dismissed Apotex's application for judicial review of the Therapeutic Products Directorate (TPD) decision which continued to require Apotex to submit additional information with respect to products manufactured or tested in its facilities in India.(1)
On 2 August 2018 the Federal Court of Appeal dismissed Apotex's appeal of the Federal Court's decision.(2) The court found that the application judge had made no reviewable error in finding that the TPD's decision was not improperly motivated and dismissed the appeal.
For further information on this topic please contact Katie Lee at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (firstname.lastname@example.org). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
(1) Further details are available here.
(2) Apotex Inc v Canada (Health), 2018 FCA 147.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.